Senior Vice President, Operations and Regulatory Affairs, Asuragen
Dr. Andruss joined in March 2006. Bernard has significant R&D experience from his progressive roles at Ambion, Inc. where he helped initiate new R&D projects and expanded Ambion’s SBIR funding program. He assisted in the spinoff of Asuragen from Ambion and built a sponsored research program that has been awarded over $25M in funding. During his tenure at Asuragen, Bernard was responsible for leading many successful diagnostic product development programs. Prior to Ambion, he worked in progressive roles at in academia at Rice University and the University of Texas M. D. Anderson Cancer Center. Dr. Andruss received his Ph.D. in Biochemistry and Cell Biology from Rice University and his B.S. in Biochemistry from Texas A&M University.
Kristine Ashcraft is a molecular biologist by training and the Head of Pharmacogenomics at Invitae. Ms. Ashcraft was the Chief Executive Officer of Youscript, Inc. during its acquisition by Invitae. She has worked in precision medicine since 2000 and was recently named one of the 25 Leading Global Voices in the space. Ms. Ashcraft has authored multiple publications on the clinical and economic benefits of pharmacogenomic testing including one lauded as one of the most influential publications at a recent AMIA meeting. She has been interviewed by numerous media outlets including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at numerous Precision Medicine Conferences. She is committed to being a catalyst in the adoption of precision medicine
Executive Director, American Society of Pharmacovigilance
A driven entrepreneur; relentless, innovative, passionate and always focused on results Benjamin Brown is Founder and Chief Executive Officer at Dynamic Life Sciences (“DLS”). DLS is a global strategy and technology consulting firm specializing in clinical and diagnostic laboratories, medical devices, genomics and personalized medicine. DLS’s team specializes in unlocking value inside companies, medical practices, accelerating business growth and securing competitive advantages by identifying opportunities using a proprietary base of technology and intelligence systems.
He advises his clients on how to build and grow exceptional companies.
When he’s not building his own companies Mr. Brown is the Executive Director of the American Society of Pharmacovigilance, a member-based organization redefining how America thinks about adverse drug events; with a mission to dramatically reduce the high rate of suffering and mortality due to adverse drug events in the US. In his role, he sets the organization’s vision, oversees the strategic direction of the Society, supports its leaders and all initiatives inside of the organization and single-mindedly focuses on accomplishing its mission.
He is very active in the pharmacogenomics community, and currently co-chairs the Pharmacogenomics, Access and Reimbursement Coalition, a global gathering of precision medicine focused professionals that actively work with and engage a wide array of stakeholders, including federal payers, commercial payers, researchers, health systems, and international organizations focused on creating new ways of thinking at the intersection of health economics, personalized medicine and value-based care. Additionally, he is actively involved in pharmacogenomics at the National Institute of Health’s, National Human Genome Research Institute, serving as member on the PGX working group (ISCC-PEG) focused on Provider Education. In 2019, he co-developed the Standardizing Laboratory Practices in Pharmacogenomics Initiative (STRIPE), which is the nation’s first and only Collaborative Community for Pharmacogenomics, supported by the FDA’s Centers for Devices and Radiological Health.
His unique, rich professional background spans from my start in investment banking, portfolio management, and sales working as a financial professional at the world’s top investment banks where I focused on providing asset and risk management solutions for families, business owners, and foundations that control significant pools of wealth and liquidity.
He is a graduate of Southern Methodist University in Dallas, TX with an undergraduate degree in Economics from the Dedman College. Mr. Brown served as Vice Chairman, and on the board of the Dallas, Texas Lone Star Wind Orchestra, a world-class wind symphony focused on inspiring people and impacting their lives through music.
Adam Buchanan, MS, MPH, LCGC, is director of the Geisinger Genomic Medicine Institute. Previously, he was a research associate at Duke Cancer Institute. He is an experienced genetic counselor and NIH-funded investigator with research interests in outcomes of genomic screening programs, service delivery models for genetics services, clinical decision support based on family health history, and assessing cancer risk management behaviors. His clinical expertise includes intimate knowledge of recommended risk management for hereditary cancer syndromes. He is co-leading Geisinger’s MyCode genomic screening program for medically actionable genomic results and is helping to develop a health services research portfolio on patient-participant, family and system outcomes of this program.
Founder and Director, Precision Medicine, Christ Hospital Health Network
Burns C. Blaxall, PhD, is the founding Director of Precision Medicine at The Christ Hospital Health Network (TCHHN). He leads efforts to transition from reactive to proactive healthcare delivery by harnessing the power of personal diagnostic and genomic data. Using approaches ranging from cutting edge hereditary disease risk assessment, genetic counseling and testing to pharmacogenomics and genome-guided clinical care pathways, precision medicine at TCHHN aims to provide proactive, individualized, clinical care for every patient.
Dr. Blaxall received his PhD in Pharmacology from the University of Colorado Health Sciences Center, followed by a postdoctoral fellowship at Duke University Medical Center. He held faculty positions at the University of Rochester Medical Center as well as at Cincinnati Children’s Hospital Medical Center, where he was Professor and founding Director of the Center for Translational Fibrosis Research, as well as Director of Translational Science and of the Heart Institute Clinical Research Core and Biorepository. He holds several patents and has received numerous honors, including the Early Career Investigator Award and the Outstanding Achievement Award (Founder’s) from the American Heart Association. He has held extensive national and international leadership positions in numerous professional societies, served on the editorial board of seven top professional journals and chaired NIH peer-review panels. He is an elected fellow of several professional organizations (AHA, ACC, ISHR, APS) and currently serves in national leadership positions for prominent professional societies in the fields of Precision Medicine and Pharmacogenomics.
Co-Founder and Chief Scientific Officer, GenXys Health Care Systems
Prof. Martin Dawes, with over 30 years of experience in research and clinical practice, is a globally renowned expert in pharmacogenetics in primary care. Following his Ph.D. at the University of Oxford, he helped develop a master’s program in Evidence-Based Health Care. He has directed the UK Centre for Evidence-Based Medicine in Oxford and was the head of family practice at McGill University and the University of British Columbia.
In 2014, he co-founded GenXys Health Care Systems, a Vancouver-based healthcare technology company that offers clinical decision support software. These programs instantly consider all relevant health information—including pharmacogenetics (PGx), comprehensive drug interactions, medical guidelines, and renal or hepatic function—to help physicians and pharmacists deliver the highest standard of evidence-based prescribing and medication reviews in a way that is tailored to their workflow. Since 2018, he has served as Specialist Medical Advisor for Babylon by TELUS Health, a healthcare mobile app that allows you to check symptoms, consult with doctors, and easily access your clinical records.
In addition to his clinical and entrepreneurial work, Prof. Dawes has a great passion for contributing to the healthcare community. He develops training programs that allow clinicians to engage in master’s level research. And when he is not at work, he enjoys spending time outdoors, fishing, and sailing.
Dr. Deverka conducts health policy studies at AIR, primarily in the area of personalized medicine with projects funded by NHGRI and PCORI. She is a recognized expert in the area of coverage and reimbursement for new genomic-based technologies and has worked collaboratively with stakeholders to recommend standards for a more predictable reimbursement pathway. Recently, she has analyzed data from a private payer coverage policy registry for NGS-based tests and led a study of policy barriers for NIPT. Dr. Deverka leads the public deliberation component of an NHGRI-funded grant to examine policy issues surrounding genomic data sharing in a medical information commons. Prior to working in the non-profit sector, she spent nearly 15 years in the pharmaceutical and PBM industries leading departments of outcomes research. She has a master’s degree in bioethics from the University of Pennsylvania and completed a policy fellowship at Duke University’s Institute for Genome Sciences and Policy.
Director, Business Development, Thermo Fisher Scientific
Jami Elliott is part of a clinical business strategy team within Thermo Fisher Scientific’s Genetic Sciences Division (GSD) where he directs new platform & test development for diagnostic segments. Jami is actively involved in CE-IVD and U.S.-IVD strategy development; as well as programs focused on Pharmacogenetics enabled medication therapy management, reimbursement and regulatory strategy.
In addition to Mr. Elliott’s work developing clinical strategy, he also leads a CLIA/ CAP, ISO15189 & ISO13485 laboratory which serves to support cross-divisional collaborations, Industry partnerships and clinical assay & medical device development. The laboratory is actively supporting health economic studies in the area of medication safety management.
Julie is a licensed pharmacist, certified in pharmacogenomics. As Senior Director of Business Development at OneOme, she works with healthcare organizations, payors, and PBMs to develop and implement pharmacogenomics programs that improve clinical and financial outcomes. She is active in local and national pharmacy organizations, including AMCP and NCPDP.
Dr. Jaya Goyal is leading preclinical safety, toxicology, bioanalytical, DMPK, clinical pharmacology and biomarker activities to support the preclinical and clinical development of nucleic acid-based therapeutics at Wave Life Sciences, Cambridge Massachusetts. The group is responsible for the creation of integrated preclinical development strategies that defines “safe use conditions” and selection of “clinical dose/regimen” based upon pharmacokinetic, pharmacodynamic and safety profiles to facilitate seamless transition of candidates from therapeutic discovery to clinical development. Her team is also responsible for clinical biomarker strategies and translational medicine approaches for patient stratification and personalized medicine. Prior to joining Wave Life Sci. in 2017, Jaya was at Biogen for 16 years, where, in her most recent role as Senior Director, she was a member of cross-functional innovation hub, Value Based Medicine (VBM), focused on improving decision making and clinical care for Multiple Sclerosis (MS) patients. Jaya received her Ph.D. degree in Biochemistry from Central Drug Research Institute, India in 1993 and did her post-doctoral training at the Rush Presbyterian St. Luke’s Medical Center, Chicago and New England Medical Center, Boston.
Christopher Grilli, Pharm.D., BCACP, of Mayo Clinic in Phoenix Arizona, is a pharmacist specializing in pharmacogenomics. Chris received his Doctorate of Pharmacy from Creighton University College of Pharmacy. In addition he is Board Certified in Ambulatory Care Pharmacy through the Board of Pharmacy Specialties. Currently he oversees outpatient pharmacy operations for Mayo Clinic Arizona. He helped found Mayo Clinic Arizona’s Ambulatory Medication Therapy Management Program as well as played an integral role in bringing a pharmacogenomics program to Arizona. Chris is actively involved in researching process improvement and healthcare delivery workflows within Mayo Clinic’s multidisciplinary practice. He also has overseen the formation of a full service compounding operation so that patients can have their medications individualized. In addition to his work at Mayo Clinic, Chris is a member of the policy committee for the American Pharmacist Association. As a member of this important committee Chris lends his expertise in pharmacogenomics to the largest professional pharmacist organization in the country.
Medical Director, Behavioral Health, Mercy Health System
Dr. Kyle John, a child/adolescent psychiatrist, has been a member of the Mercy Health System since 2007. In addition to clinical practice, he most recently served as Medical Director for Behavioral Health at Mercy’s Virtual Care Center and currently serves as Medical Director for Behavioral Health in Mercy’s East region. Dr. John received his undergraduate and medical education from University of Missouri, Columbia. He completed his adult and child psychiatry residencies at Mayo Clinic, Rochester, MN, and is board certified by the American Board of Psychiatry and Neurology.
Program Director of Education, Outpatient Pharmacy
Mayo Clinic Department of Pharmacy, Phoenix
Adrijana Kekic, Pharm D, is a Program Director of Education, Outpatient Pharmacy at Mayo Clinic in Phoenix, Arizona. She is active in clinical care, research and lecturing and has been involved in development of pharmacogenomics services and education. She is a licensed pharmacist in Arizona.
Dr. Kekic earned the Doctor of Pharmacy degree from Midwestern University College of Pharmacy in Glendale, Arizona. She is board certified ambulatory care pharmacist through Board Pharmacy Specialties (BPS) and a member of BPS Ambulatory Care Committee. She holds a certification in Pharmacogenomics from University of Florida College of Pharmacy and is pursuing a Genomic Medicine certification from Stanford University.
Adrijana has served as an adjunct faculty at Midwestern University College of Pharmacy and an instructor, preceptor and residency preceptor at Mayo School of Medical Science. She is involved with several pharmacogenomics research projects and studies in palliative care, transplant care, anesthesia and cardiology. She sits on Pharmacogenomics Task Force at Mayo Clinic.
With two decades of clinical experience and expertise in medication therapy management , Adrijana continues to advance pharmacy practice and pharmacy leadership. She is a founder of a networking platform dedicated to high impact professional women in healthcare. She lives in Arizona with her husband and son, where they enjoy hiking. Besides pharmacogenomics, her interest include languages, history, visual arts, martial arts and healthy living.
Chair, Department of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, Associate Professor, Hematology/Oncology
Dr. Patel joined the Levine Cancer Institute as Chief of Pharmacology Research in 2013 and currently serves as Chair of the Department of Cancer Pharmacology and Pharmacogenomics and Associate Professor in the Division of Hematology/Oncology. Dr. Patel’s research focuses on translational and clinical pharmacogenomics and pharmacokinetics of anticancer therapies. He serves as a part-time palliative medicine clinical pharmacist and also has research interests in supportive oncology and management of venous thromboembolism in cancer patients.
Population Health Supervisor, Navitus Health Solutions
Dr. Tina Patel is a clinical pharmacist and serves as Population Health Supervisor at Navitus Health Solutions. She developed and leads the PGx program at Navitus. Tina strives to provide clients with innovative solutions to lower risk of adverse events and improve patient outcomes.
Director, Clinical Affairs, American Society of Pharmacovigilance
Sara Rogers is the Director of Clinical Affairs at ASP and leads the Society’s clinical, research, and educational initiatives. She also chairs the Pharmacogenomics Access and Reimbursement Coalition to address barriers to patient access and payer coverage for pharmacogenetics testing. As a clinician-scientist, Dr. Rogers conducts patient-centered research aimed at understanding the ethical and practical implications of pharmacogenomics. Prior to serving in these roles, Dr. Rogers was an Ambulatory Treatment Center Pharmacist at the University of Texas MD Anderson Cancer Center.
She received her PharmD from the University of Houston College of Pharmacy and holds a bachelor’s in from the University of Texas at Austin with a concentration in biology.
Jeffrey Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences where he oversees the company’s research, education, and clinical programs and leads efforts focused on bridging the gap between genetic science and clinical application. Dr. Shaman brings years of experience in advising cross-functional teams together with his scholarship in genetics, pharmacology, stem cells, and clinical laboratory operations. Along with the CEO, he forges strategic partnerships with worldwide companies, laboratories, academic institutions, public/private self-insured companies, and federal, state, and regional healthcare and employee systems.
Dr. Shaman supports a team of scientists dedicated to precision medicine and who actively research, publish, and present findings in top-tier peer-reviewed journals. He is passionate about educating people from all backgrounds about the power of genetics and pharmacogenomic testing that is integrated with patient health history and clinical decision-support to proactively promote better health.
Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology. Dr. Shaman held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation.